Apheresis as Therapy
Aferetica is an Innovative Small and Medium-sized Enterprise (SME), founded by Managers with tens of years of experience in Dialysis, Intensive Care, Cardiology and Medical Devices.
The company proposes itself as a catalyst for the creation of a Network of Clinicians, Academics, Researchers and Institutions, to create and validate New Apheretic Therapies, even for unexplored clinical areas.
An integrated and innovative vision of apheretic therapies is the challenge to face for a real evolution of the cure.
Our Therapeutic Systems
Products, knowledges, therapeutic protocols and clinical research.
Last updates
The integrated PerLife(R) system with “PerSorb ECOS-300CY™” sorbent obtains CE certification and is ready to enter in the clinical practice.
CytoSorbents (USA) and Aferetica announce the European Union's approval for clinical use of the integrated PerLife® system and the "PerSorb ECOS-300CY ™" sorbent
Second update on the possible use of CytoSorb in patients affected by COVID-19
Second update on the news related to the possible use of CytoSorb as an adjuvant therapy against some complications in patients with severe COVID-19 infection
Update on the possible use of CytoSorb in patients affected by COVID-19
We consider important to share an update on the news related to the possible use of CytoSorb as an adjuvant therapy against some complications in patients with severe infection with COVID-19
Events
31° SMART- Virtual Meeting (13th-15th November)
Extracorporeal Therapies in sepsis’ session on the 13th of November from 2.30 tp 4.00 pm.
38th Vicenza Course on AKI & CRRT – a week of virtual meetings
AKI & Sepsi and AKI & biomarkers Sessions on the 2nd of November 2nd, from 1.30pm.
WEB SYMPOSIUM – 17 th November 2020
Early Identification of Sepsis: Serial point-of-care measurements of Pancreatic Stone Protein (PSP) in the critically ill